# Safety and Potency of a High Cabergoline Dosage in Microprolactinomas

Source: https://onco.cc/trials/nct07463235/  
OnCo record `nct07463235` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cabergoline in Pituitary tumours, run by University of Sao Paulo General Hospital, now recruiting.

## Summary

Safety and Potency of a High Cabergoline Dosage in Microprolactinomas is a phase 3 interventional study registered as NCT07463235 by University of Sao Paulo General Hospital, with 70 participants planned, started 2026-03-04 and due to reach its primary completion in 2027-08-20. Interventions recorded: Cabergoline, Cabergoline. Conditions recorded: Prolactinoma, Prolactin Excess.

Linked to the drug Cabergoline because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07463235
- Phase: 3
- Setting: Safety and Potency of a High Cabergoline Dosage in Microprolactinomas
- Sponsor: University of Sao Paulo General Hospital
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT07463235: https://clinicaltrials.gov/study/NCT07463235

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- drugs: [Cabergoline](https://onco.cc/drugs/cabergoline/)

---
JSON: https://onco.cc/api/v1/entities/nct07463235.json